Peptides and Oligonucleotides, common trends as drugs

10

Last year in this same forum, we affirmed that we are witnessing a golden age of peptides and oligonucleotides as pharmaceuticals (1). In this regard, from 1 January 2016 to 30 April 2023, the US Food and Drug Administration (FDA) approved 31 new drugs whose active pharmaceutical ingredients (APIs) contain peptides (Table 1). This list includes six radioactive peptide‐based thera/diagnostic agents and four antibody drug conjugates (ADCs) with a peptide drug.